Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses are infrequent, and acquired resistance to Bruton agammaglobulinemia tyrosine kinase (BTK) inhibition is being observed in an increasing number of patients. Combination regimens that increase freq...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Hing, Zachary A., Mantel, Rose, Beckwith, Kyle A., Guinn, Daphne, Williams, Erich, Smith, Lisa L., Williams, Katie, Johnson, Amy J., Lehman, Amy M., Byrd, John C., Woyach, Jennifer A., Lapalombella, Rosa
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4432007/
https://ncbi.nlm.nih.gov/pubmed/25838351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-621391
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados